{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:21:59Z","timestamp":1786980119315,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100010041","name":"Tianjin Science and Technology Committee","doi-asserted-by":"publisher","award":["2017ZXMFSY00070"],"award-info":[{"award-number":["2017ZXMFSY00070"]}],"id":[{"id":"10.13039\/501100010041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00406-021-01359-4","type":"journal-article","created":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T19:03:47Z","timestamp":1642359827000},"page":"633-642","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia"],"prefix":"10.1007","volume":"272","clinical-trial-number":[{"clinical-trial-number":"nct03548155","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Meijuan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoduo","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5408-8413","authenticated-orcid":false,"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,17]]},"reference":[{"key":"1359_CR1","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S2215-0366(18)30345-6","volume":"5","author":"B Deakin","year":"2018","unstructured":"Deakin B, Suckling J, Barnes T, Byrne K, Chaudhry I, Dazzan P, Drake R, Giordano A, Husain N, Jones P et al (2018) The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial. Lancet Psychiatry 5:885\u2013894","journal-title":"Lancet Psychiatry"},{"key":"1359_CR2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/NDT.S225643","volume":"16","author":"C Correll","year":"2020","unstructured":"Correll C, Schooler N (2020) Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treatment 16:519\u2013534","journal-title":"Neuropsychiatr Dis Treatment"},{"key":"1359_CR3","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","volume":"174","author":"S Leucht","year":"2017","unstructured":"Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, Samara M, Rabaioli M, B\u00e4cher S, Cipriani A et al (2017) Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry 174:927\u2013942","journal-title":"Am J Psychiatry"},{"key":"1359_CR4","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2021.13","volume":"64","author":"S Galderisi","year":"2021","unstructured":"Galderisi S, Kaiser S, Bitter I, Nordentoft M, Mucci A, Sab\u00e9 M, Giordano GM, Nielsen M, Glenth\u00f8j LB, Pezzella P et al (2021) EPA guidance on treatment of negative symptoms in schizophrenia. Eur Psychiatry 64:e21","journal-title":"Eur Psychiatry"},{"key":"1359_CR5","first-page":"166","volume":"2","author":"A Abi-Dargham","year":"2003","unstructured":"Abi-Dargham A (2003) Probing cortical dopamine function in schizophrenia: what can D1 receptors tell us? World Psychiatry 2:166\u2013171","journal-title":"World Psychiatry"},{"key":"1359_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.tins.2018.12.004","volume":"42","author":"R McCutcheon","year":"2019","unstructured":"McCutcheon R, Abi-Dargham A, Howes O (2019) Schizophrenia, dopamine and the striatum: from biology to symptoms. Trends Neurosci 42:205\u2013220","journal-title":"Trends Neurosci"},{"key":"1359_CR7","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1093\/schbul\/sbs092","volume":"39","author":"L Rowland","year":"2013","unstructured":"Rowland L, Kontson K, West J, Edden R, Zhu H, Wijtenburg S, Holcomb H, Barker P (2013) In vivo measurements of glutamate, GABA, and NAAG in schizophrenia. Schizophr Bull 39:1096\u20131104","journal-title":"Schizophr Bull"},{"key":"1359_CR8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.schres.2018.02.048","volume":"199","author":"D Goldsmith","year":"2018","unstructured":"Goldsmith D, Haroon E, Miller A, Strauss G, Buckley P, Miller B (2018) TNF-\u03b1 and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia. Schizophr Res 199:281\u2013284","journal-title":"Schizophr Res"},{"key":"1359_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.pnpbp.2018.04.006","volume":"86","author":"E Liemburg","year":"2018","unstructured":"Liemburg E, Nolte I, Klein H, Knegtering H (2018) Relation of inflammatory markers with symptoms of psychotic disorders: a large cohort study. Progr Neuropsychopharmacol Biol Psychiatry 86:89\u201394","journal-title":"Progr Neuropsychopharmacol Biol Psychiatry"},{"key":"1359_CR10","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3389\/fpubh.2017.00360","volume":"5","author":"T Boozalis","year":"2017","unstructured":"Boozalis T, Teixeira A, Cho R, Okusaga O (2017) C-reactive protein correlates with negative symptoms in patients with schizophrenia. Front Public Health 5:360","journal-title":"Front Public Health"},{"key":"1359_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.psyneuen.2013.12.005","volume":"41","author":"A Stojanovic","year":"2014","unstructured":"Stojanovic A, Martorell L, Montalvo I, Ortega L, Monseny R, Vilella E, Labad J (2014) Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms. Psychoneuroendocrinology 41:23\u201332","journal-title":"Psychoneuroendocrinology"},{"key":"1359_CR12","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3389\/fnins.2018.00296","volume":"12","author":"F Zhu","year":"2018","unstructured":"Zhu F, Zhang L, Liu F, Wu R, Guo W, Ou J, Zhang X, Zhao J (2018) Altered serum tumor necrosis factor and interleukin-1\u03b2 in first-episode drug-naive and chronic schizophrenia. Front Neurosci 12:296","journal-title":"Front Neurosci"},{"key":"1359_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2020.12.020","volume":"230","author":"D Enache","year":"2021","unstructured":"Enache D, Nikkheslat N, Fathalla D, Morgan BP, Lewis S, Drake R, Deakin B, Walters J, Lawrie SM, Egerton A et al (2021) Peripheral immune markers and antipsychotic non-response in psychosis. Schizophr Res 230:1\u20138","journal-title":"Schizophr Res"},{"key":"1359_CR14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3389\/fpsyt.2020.00046","volume":"11","author":"D Goldsmith","year":"2020","unstructured":"Goldsmith D, Rapaport M (2020) Inflammation and negative symptoms of schizophrenia: implications for reward processing and motivational deficits. Front Psych 11:46","journal-title":"Front Psych"},{"key":"1359_CR15","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1177\/0269881112444941","volume":"26","author":"I Chaudhry","year":"2012","unstructured":"Chaudhry I, Hallak J, Husain N, Minhas F, Stirling J, Richardson P, Dursun S, Dunn G, Deakin B (2012) Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol 26:1185\u20131193","journal-title":"J Psychopharmacol"},{"key":"1359_CR16","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.schres.2014.01.011","volume":"153","author":"F Liu","year":"2014","unstructured":"Liu F, Guo X, Wu R, Ou J, Zheng Y, Zhang B, Xie L, Zhang L, Yang L, Yang S et al (2014) Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. Schizophr Res 153:169\u2013176","journal-title":"Schizophr Res"},{"key":"1359_CR17","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.schres.2018.03.003","volume":"199","author":"F Liu","year":"2018","unstructured":"Liu F, Zhang B, Xie L, Ruan Y, Xu X, Zeng Y, Messina L, Zhao J, Fan X (2018) Changes in plasma levels of nitric oxide metabolites and negative symptoms after 16-week minocycline treatment in patients with schizophrenia. Schizophr Res 199:390\u2013394","journal-title":"Schizophr Res"},{"key":"1359_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.pnpbp.2018.04.004","volume":"85","author":"L Zhang","year":"2018","unstructured":"Zhang L, Zheng H, Wu R, Zhu F, Kosten T, Zhang X, Zhao J (2018) Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: association with pro-inflammatory cytokine levels. Progr Neuropsychopharmacol Biol Psychiatry 85:69\u201376","journal-title":"Progr Neuropsychopharmacol Biol Psychiatry"},{"key":"1359_CR19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/ptr.2968","volume":"24","author":"S Kulkarni","year":"2010","unstructured":"Kulkarni S, Dhir A (2010) Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders. Phytother Res 24:317\u2013324","journal-title":"Phytother Res"},{"key":"1359_CR20","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ejphar.2015.05.068","volume":"761","author":"A Kumar","year":"2015","unstructured":"Kumar A, Ekavali CK, Mukherjee M, Pottabathini R, Dhull D (2015) Current knowledge and pharmacological profile of berberine: an update. Eur J Pharmacol 761:288\u2013297","journal-title":"Eur J Pharmacol"},{"key":"1359_CR21","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/cmdc.200600303","volume":"2","author":"T Tarrago","year":"2007","unstructured":"Tarrago T, Kichik N, Segu\u00ed J, Giralt E (2007) The natural product berberine is a human prolyl oligopeptidase inhibitor. Chem Med Chem 2:354\u2013359","journal-title":"Chem Med Chem"},{"key":"1359_CR22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.neulet.2019.05.029","volume":"706","author":"S GhotbiRavandi","year":"2019","unstructured":"GhotbiRavandi S, Shabani M, Bashiri H, SaeediGoraghani M, Khodamoradi M, Nozari M (2019) Ameliorating effects of berberine on MK-801-induced cognitive and motor impairments in a neonatal rat model of schizophrenia. J Neurosci Lett 706:151\u2013157","journal-title":"J Neurosci Lett"},{"key":"1359_CR23","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.brainresbull.2017.08.008","volume":"134","author":"Y Liu","year":"2017","unstructured":"Liu Y, Niu L, Wang L, Bai L, Fang X, Li Y, Yi L (2017) Berberine attenuates depressive-like behaviors by suppressing neuro-inflammation in stressed mice. Brain Res Bull 134:220\u2013227","journal-title":"Brain Res Bull"},{"key":"1359_CR24","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.intimp.2016.06.031","volume":"38","author":"Z Zhang","year":"2016","unstructured":"Zhang Z, Li X, Li F, An L (2016) Berberine alleviates postoperative cognitive dysfunction by suppressing neuroinflammation in aged mice. Int Immunopharmacol 38:426\u2013433","journal-title":"Int Immunopharmacol"},{"key":"1359_CR25","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","volume":"42","author":"S Leucht","year":"2016","unstructured":"Leucht S, Samara M, Heres S, Davis J (2016) Dose equivalents for antipsychotic drugs: the DDD method. Schizophr Bull 42:S90\u2013S94","journal-title":"Schizophr Bull"},{"key":"1359_CR26","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12967-016-0982-x","volume":"14","author":"X Chang","year":"2016","unstructured":"Chang X, Wang Z, Zhang J, Yan H, Bian H, Xia M, Lin H, Jiang J, Gao X (2016) Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease. J Transl Med 14:266","journal-title":"J Transl Med"},{"key":"1359_CR27","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/j.1440-1681.2012.05670.x","volume":"39","author":"S Meng","year":"2012","unstructured":"Meng S, Wang L, Huang Z, Zhou Q, Sun Y, Cao J, Li Y, Wang C (2012) Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention. Clin Exp Pharmacol Physiol 39:406\u2013411","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"1359_CR28","first-page":"7","volume":"45","author":"M Steven","year":"1996","unstructured":"Steven M, Haffner RDA Jr, Saad MF, Rewers M, Mykkanen L, Joseph Selby GH, Savage PJ, Hamman RF, Wagenknecht LE, Bergman RN (1996) Increased insulin resistance and insulin secretion in nondiabetic African-Americans and hispanics compared with non-hispanic whites. Diabetes 45:7","journal-title":"Diabetes"},{"key":"1359_CR29","doi-asserted-by":"publisher","first-page":"107704","DOI":"10.1016\/j.neuropharm.2019.107704","volume":"172","author":"SJ Kaar","year":"2020","unstructured":"Kaar SJ, Natesan S, McCutcheon R, Howes OD (2020) Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology 172:107704","journal-title":"Neuropharmacology"},{"key":"1359_CR30","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, Arndt T, B\u00e4ckers L, Rothe P, Cipriani A et al (2019) Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet (Lond, Engl) 394:939\u2013951","journal-title":"Lancet (Lond, Engl)"},{"key":"1359_CR31","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.pharmthera.2011.06.003","volume":"132","author":"U Meyer","year":"2011","unstructured":"Meyer U, Schwarz M, M\u00fcller N (2011) Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative\/cognitive symptoms and beyond. Pharmacology therapeutics 132:96\u2013110","journal-title":"Pharmacology therapeutics"},{"key":"1359_CR32","doi-asserted-by":"publisher","first-page":"138","DOI":"10.4088\/JCP.08m04666yel","volume":"71","author":"Y Levkovitz","year":"2010","unstructured":"Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, Fennig S, Treves I, Kron S (2010) A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 71:138\u2013149","journal-title":"J Clin Psychiatry"},{"key":"1359_CR33","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2174\/1570159X16666180119144538","volume":"16","author":"L Orsolini","year":"2018","unstructured":"Orsolini L, Sarchione F, Vellante F, Fornaro M, Matarazzo I, Martinotti G, Valchera A, Di Nicola M, Carano A, Di Giannantonio M et al (2018) Protein-C reactive as biomarker predictor of schizophrenia phases of Illness? A systematic review. Curr Neuropharmacol 16:583\u2013606","journal-title":"Curr Neuropharmacol"},{"key":"1359_CR34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.psychres.2011.05.010","volume":"190","author":"MH Fawzi","year":"2011","unstructured":"Fawzi MH, Fawzi MM, Fawzi MM, Said NS (2011) C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia. Psychiatry Res 190:91\u201397","journal-title":"Psychiatry Res"},{"key":"1359_CR35","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.schres.2015.08.019","volume":"168","author":"J Joseph","year":"2015","unstructured":"Joseph J, Depp C, Martin A, Daly R, Glorioso D, Palmer B, Jeste D (2015) Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups. Schizophr Res 168:456\u2013460","journal-title":"Schizophr Res"},{"key":"1359_CR36","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/mp.2015.87","volume":"21","author":"B Fernandes","year":"2016","unstructured":"Fernandes B, Steiner J, Bernstein H, Dodd S, Pasco J, Dean O, Nardin P, Gon\u00e7alves C, Berk M (2016) C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. Mol Psychiatry 21:554\u2013564","journal-title":"Mol Psychiatry"},{"key":"1359_CR37","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.3892\/etm.2017.4402","volume":"13","author":"L Zhang","year":"2017","unstructured":"Zhang L, Wang Y, Tong L, Sun S, Liu W, Zhang S, Wang R, Wang Z, Li L (2017) Berberine alleviates dextran sodium sulfate-induced colitis by improving intestinal barrier function and reducing inflammation and oxidative stress. Exp Ther Med 13:3374\u20133382","journal-title":"Exp Ther Med"},{"key":"1359_CR38","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.3892\/mmr.2017.6353","volume":"15","author":"X Zhu","year":"2017","unstructured":"Zhu X, Sun Y, Zhang C, Liu H (2017) Effects of berberine on a rat model of chronic stress and depression via gastrointestinal tract pathology and gastrointestinal flora profile assays. Mol Med Rep 15:3161\u20133171","journal-title":"Mol Med Rep"},{"key":"1359_CR39","first-page":"3009","volume":"17","author":"C Cao","year":"2019","unstructured":"Cao C, Su M (2019) Effects of berberine on glucose-lipid metabolism, inflammatory factors and insulin resistance in patients with metabolic syndrome. Exp Ther Med 17:3009\u20133014","journal-title":"Exp Ther Med"},{"key":"1359_CR40","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ctim.2019.08.002","volume":"46","author":"M Beba","year":"2019","unstructured":"Beba M, Djafarian K, Shab-Bidar S (2019) Effect of Berberine on C-reactive protein: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Med 46:81\u201386","journal-title":"Complement Ther Med"},{"key":"1359_CR41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.neulet.2016.01.002","volume":"614","author":"J Shen","year":"2016","unstructured":"Shen J, Ma L, Hu C, Pei Y, Jin S, Fang X, Li Y (2016) Berberine up-regulates the BDNF expression in hippocampus and attenuates corticosterone-induced depressive-like behavior in mice. Neurosci Lett 614:77\u201382","journal-title":"Neurosci Lett"},{"key":"1359_CR42","first-page":"53","volume":"21","author":"M Aski","year":"2018","unstructured":"Aski M, Rezvani M, Khaksari M, Hafizi Z, Pirmoradi Z, Niknazar S, Mehrjerdi F (2018) Neuroprotective effect of berberine chloride on cognitive impairment and hippocampal damage in experimental model of vascular dementia. Iran J Basic Med Sci 21:53\u201358","journal-title":"Iran J Basic Med Sci"},{"key":"1359_CR43","doi-asserted-by":"publisher","first-page":"109670","DOI":"10.1016\/j.biopha.2019.109670","volume":"121","author":"Y Chen","year":"2020","unstructured":"Chen Y, Chen Y, Liang Y, Chen H, Ji X, Huang M (2020) Berberine mitigates cognitive decline in an Alzheimer\u2019s Disease Mouse Model by targeting both tau hyperphosphorylation and autophagic clearance. Biomed Pharmacother 121:109670","journal-title":"Biomed Pharmacother"},{"key":"1359_CR44","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s13205-020-02354-7","volume":"10","author":"W Xuan","year":"2020","unstructured":"Xuan W, Wang H, Zhou P, Ye T, Gao H, Ye S, Wang J, Chen M, Song H, Wang Y et al (2020) Berberine ameliorates rats model of combined Alzheimer\u2019s disease and type 2 diabetes mellitus via the suppression of endoplasmic reticulum stress. 3 Biotech 10:359","journal-title":"3 Biotech"},{"key":"1359_CR45","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S2468-1253(19)30409-1","volume":"5","author":"YX Chen","year":"2020","unstructured":"Chen YX, Gao QY, Zou TH, Wang BM, Liu SD et al (2020) Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study. Lancet Gastroenterol Hepatol 5:267\u2013275","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1359_CR46","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jep.2014.09.049","volume":"161","author":"J Lan","year":"2015","unstructured":"Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J, Sun G (2015) Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol 161:69\u201381","journal-title":"J Ethnopharmacol"},{"key":"1359_CR47","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2021.11","volume":"64","author":"S Galderisi","year":"2021","unstructured":"Galderisi S, Mucci A, Dollfus S, Nordentoft M, Falkai P, Kaiser S, Giordano GM, Vandevelde A, Nielsen M, Glenth\u00f8j LB et al (2021) EPA guidance on assessment of negative symptoms in schizophrenia. Eur Psychiatry 64:e23","journal-title":"Eur Psychiatry"},{"key":"1359_CR48","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1192\/bjp.166.5.654","volume":"166","author":"SH Jones","year":"1995","unstructured":"Jones SH, Thornicroft G, Coffey M, Dunn G (1995) A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 166:654\u2013659","journal-title":"Br J Psychiatry"},{"key":"1359_CR49","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.schres.2015.09.003","volume":"169","author":"C Shi","year":"2015","unstructured":"Shi C, Kang L, Yao S, Ma Y, Li T, Liang Y, Cheng Z, Xu Y, Shi J, Xu X et al (2015) The MATRICS Consensus Cognitive Battery (MCCB): co-norming and standardization in China. Schizophr Res 169:109\u2013115","journal-title":"Schizophr Res"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-021-01359-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-021-01359-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-021-01359-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T02:04:43Z","timestamp":1652234683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-021-01359-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,17]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1359"],"URL":"https:\/\/doi.org\/10.1007\/s00406-021-01359-4","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,17]]},"assertion":[{"value":"4 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"XF has received research support or honoraria from Alkermes, Neurocrine, Avanir, Allergen, Otsuka, Lundbeck, Boehringer Ingelheim, Merck, and Janssen. Other authors report no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The supporters had no role in the design, analysis, interpretation, or publication of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of the sponsors"}}]}}